Ron Petersen on Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit
COMMENT I think the donanemab data are interesting and possibly encouraging. The key features are: Donanemab lowers amyloid promptly and significantly to essentially normal levels; Once normalized, the sponsor stopped dosing; The incidence of ARIA was significant ...